Leflunomide
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Leflunomide: From DMARD/Immunomodulator to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Leflunomide is a known dihydroorotate dehydrogenase (DHODH) inhibitor used clinically as a disease-modifying antirheumatic drug (DMARD) / immunomodulator; its specific original indication record is not yet available in this dataset. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare developmental limb disorder, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-output-only signal with no independent mechanistic, trial, or literature corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset (drug is a known DHODH inhibitor / DMARD immunomodulator per mechanistic notes; formal indication text pending) |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for leflunomide is marked as a data gap in this evidence pack. Based on generally known pharmacology referenced in the model's own rationale notes, leflunomide inhibits dihydroorotate dehydrogenase (DHODH), thereby suppressing pyrimidine synthesis and lymphocyte proliferation — this is the basis for its established use as an immunomodulatory DMARD.
Brachydactyly-syndactyly syndrome, however, is a rare congenital disorder of limb development, typically driven by mutations in developmental patterning genes such as HOXD or GLI3. There is no known overlap between DHODH/pyrimidine-synthesis inhibition and the developmental gene pathways implicated in this syndrome.
The repurposing rationale for this candidate explicitly states that no mechanistic link can be established — the prediction reflects a high-scoring knowledge-graph association from the TxGNN algorithm alone, without biological plausibility support. This should be treated as a hypothesis-generating signal only, not as evidence of therapeutic relevance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Leflunomide currently has no marketing authorizations recorded (0 licenses; market status: Not Marketed). No product table is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by an L5 (model-prediction-only) evidence level, with no clinical trials or literature identified, and the repurposing rationale itself states no mechanistic plausibility could be established between leflunomide's known DHODH-inhibitory action and the pathology of brachydactyly-syndactyly syndrome. Combined with a Blocking-severity data gap on TFDA label warnings/contraindications, this candidate cannot proceed to safety pre-screening (S1).
To proceed, the following is needed:
- TFDA label (warnings/contraindications) — required before any S1 safety evaluation (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Independent mechanistic or preclinical rationale linking DHODH/pyrimidine synthesis inhibition to limb developmental disorders
- Any emerging clinical trial or case-report literature for this indication
Note: A second candidate indication, colobomatous microphthalmia-rhizomelic dysplasia syndrome (TxGNN score 99.93%, rank 1084), carries the same L5 evidence level, zero trial/literature support, and an equivalent "no mechanistic link established" conclusion. It is likewise recommended for Hold pending the same data gaps above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.